MUNICH (Reuters) – Siemens AG (OTC:SIEGY) is reviewing its majority stake in medical technology subsidiary Siemens (ETR:SIEGn) Healthineers,, the German technology group’s Chief Financial Officer Ralf Thomas told the Handelsblatt newspaper.
The synergies with the manufacturer of MRI machines and laboratory systems are not great enough to justify a capital commitment of 45 billion euros ($46.91 billion), Thomas told Handelsblatt, referring to how much Siemens’ 75% equity stake is worth.
“We are evaluating the economic opportunities for Siemens AG in the healthcare sector. We will then derive from this how instrumental Healthineers is as an investment. And then we will draw a conclusion from that,” he said, adding that the results will be presented at a capital markets day at the end of 2025.
Siemens AG spun off the Erlangen, Germany-based subsidiary in 2018 and floated it on the stock exchange. Until now, Siemens had maintained it would keep the majority stake in Siemens Healthineers.
However, Thomas recently held out the prospect of selling around 5% in the foreseeable future to finance the takeover of U.S. software company Altair.
Thomas said he remained committed to the Mobility train division, which investors have repeatedly called to be spun off.
“The business is in good hands with us. I don’t see any need for us to part with it at the moment,” he told Handelsblatt.
($1 = 0.9592 euros)